We're looking for people who have participated in a psychedelic trial to review materials for a new study. It's a paid opportunity (about 4 hours). Your experience could really help future participants.
Have you had a challenging psychedelic experience and then sought therapeutic help afterwards?
Therapist and friend of The MPS, Amy Durden, is looking for participants to complete a semi-structured interview. More info below 📎:
We are recruiting a band 6 nurse to work alongside The Psychoactive Trials Group on our psilocybin trials. Employed via SLaM, both physical and mental health nurses welcome to apply. 📝Details here: https://t.co/3phwmlkpTi
What role, if any, can psychedelic drugs play in treating mental health conditions? And how do they affect women?
@itsanitarani discusses the latest research with @ProfDavidNutt and Catherine Bird @catbirdmeow
🎧 Listen from 10am ⬇️
This will be the most in depth talk I've ever given about my preliminary superscale machine learning analysis of how psychedelics and other drugs associate with different cognitive performance patterns; come along as you'll be in for a treat!
Why is it so difficult to research #psilocybin?
Following yesterday's parliamentary debate on rescheduling the drug, @drjrucker spoke to @BBCNewsnight about the difficulties some institutions face.
#IoPPNInTheNews
Footage C/O BBC Newsnight and @katelamble
🌟Recruitment is open for a study to evaluate the safety and tolerability of the psychedelic 5-MeO-DMT (BPL-003), with psychological support, in individuals with treatment resistant #depression in South East London.
Please share! https://t.co/SN1kDLBD7c
⭐️ATTENTION⭐️ Recruitment is ongoing for individuals with #depression for a #ketamine brain imaging study in South East London. 11 visits over 2-3 months. Visit https://t.co/ZCM5tJMjcs or email [email protected] for info.
Please share!
🚨New preprint alert!🚨
1/ We developed and validated the Psychedelic Preparedness Scale (PPS), a tool to assess how well-prepared participants are for psychedelic experiences.
https://t.co/yz8qi7zoi1
@rhizoqualia@sunjeevk@UCL_CPU@PsychedelicUNIT
Largest #psilocybin for TRD study published in @NEJM with solid signal to move onto phase 3. Grateful to have been part of the brilliant @KingsIoPPN team, led by @drjrucker. We have learnt so much, but plenty more questions remain. Onwards! https://t.co/mBKIN8wlEx